RUNX2 and cancer: A substantial therapeutic advancement in the treatment of cancer can be achieved by reversing the gene specific 5′ promoter CpG methylation [52], and methyl sequencing studies confirmed that kaempferol at a tested dose of 30 μM (48 h) has shown a significant reduction in 5′ CpG promoter methylation and consequent reactivation of TSGs such as TP53, DAPK1, PAX2, PAX1, PAX6, PTEN (PINK1), RASSF1, WIF1, VHL, RUNX1, RUNX2, RARβ, SOCS1, SOX1, FOXO3, PERP, TIMP 2, TIMP 3, APC2, PCDH1, CDH13 and so forth compared to control (Figure 5a).